• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Inspire soars on Q1 sales projection

Inspire soars on Q1 sales projection

April 14, 2020 By Sean Whooley

Inspire Medical Systems (NYSE:INSP) shares shot up more than 8% today on a first-quarter revenue projection of approximately $21.3 million, up 31% from the $16.3 million it pulled in during the first quarter of 2019.

Shares of INSP were up 8.2% at $68.61 per share in mid-afternoon trading today.

Inspire also withdrew its full-year guidance today in response to the ongoing COVID-19 pandemic. In February, the company said it expected full-year 2020 revenue to be in the range of $115 million to $119 million. As of March 31, 2020, the sleep apnea treatment developer had approximately $142 million in cash, cash equivalents and investments, down $14 million from the $156 million it held as of Dec. 31, 2019.

Inspire said it can’t predict the extent or duration of the impact coronavirus will have on financial results, but plans to provide more information during its first-quarter earnings call in May.

“The COVID-19 global health pandemic continues to cause meaningful complications to daily life and business operations,” Inspire president & CEO Tim Herbert said in the release. “The Inspire team is grateful to the healthcare professionals around the world who are selflessly caring for patients on the front lines of this pandemic, and our thoughts go out to all who have been affected.”

Inspire also announced the pricing of an underwritten public offering of 2 million shares of its common stock totaling approximately $116 million. The offering includes the shares of common stock priced at $58 per share, before underwriting discounts and commissions. Minneapolis-based Inspire also granted underwriters a 30-day option to purchase up to an additional 300,000 shares of common stock at the public offering price.

All shares are set to be sold by Inspire, which expects the offering to close on April 16, 2020, subject to closing conditions, according to a news release.

BofA Securities, J.P. Morgan and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering. Guggenheim Securities and SVB Leerink are acting as lead managers.

Filed Under: Business/Financial News, Featured, Funding Roundup, MassDevice Earnings Roundup, Respiratory, Wall Street Beat Tagged With: coronavirus, COVID-19, Inspire Medical Systems Inc.

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy